Innate and Adaptive Immune Consequences of Necroptosis

坏死性凋亡的先天性和适应性免疫后果

基本信息

项目摘要

PROPOSAL SUMMARY The innate immune system responds to perturbations in tissue homeostasis resultant from infection but also dying cells and tissue damage. Cells die by different modes of programmed cell death including apoptosis and necroptosis. Cell death by apoptosis is a normal component of healthy tissue physiology that is balanced by cell division and maintains normal tissue size and function. Cell death by apoptosis is tolerogenic and non- inflammatory, and contrasts with necroptosis, which is pathological and inflammatory. Necroptosis involves the formation of a complex of receptor interacting serine/threonine protein kinases RIPK1, RIPK3 and the necroptosis effector mixed lineage kinase domain-like protein (MLKL). Up until recently, necroptosis was thought to function primarily in the control of infection and mainly as a fail-safe strategy that counters viral blockade of apoptosis. Studies in mouse models, however, have shown that deficiency in components of the apoptosis machinery such as caspase-8 or FADD leads to embryonic lethality driven by necroptosis and dependent on RIPK3 and MLKL. Other studies using conditional deletion of caspase-8 or FADD in the intestinal epithelium revealed that blocking the pathways that mediate homeostatic apoptosis precipitates intestinal inflammation associated with elevated levels of RIPK3 and necroptosis. Indeed, a notable increase in programmed cell death of intestinal epithelial cells (IEC) has been reported in patients with inflammatory bowel disease (IBD), and this damage is associated with heightened inflammation and increased levels of tumor necrosis factor (TNF)-a, an important mediator of cell death. Using a novel mouse model where we can inducibly trigger necroptosis of IEC, we will determine how IEC necroptosis impacts intestinal homeostasis and we will define the nature of the inflammatory response. Our previous work has established that homeostatic apoptosis within the intestinal epithelium is a major driver of immune suppression and tolerance, imprinting intestinal mononuclear phagocytes (MNP) with ‘suppression of inflammation’ and ‘induction of regulatory CD4 T cell’ transcriptional signatures. Here we will define how necroptosis impacts MNP responses. We will examine the composition and characteristics of the small intestinal MNP population that responds to necroptotic IEC and decipher its function in various innate immune functions relating to the production of inflammatory mediators, modulation of innate lymphoid cell function as well as the CD4 T helper cell differentiation. The knowledge we gain will define how necroptosis drives inflammatory responses by innate and adaptive populations of cells, serve as a roadmap for the consequences of necroptosis in other tissues, and lay the foundation for the development of novel therapeutics for chronic inflammatory diseases such as IBD.
提案摘要 先天免疫系统对感染的组织稳态扰动做出反应,但也 垂死的细胞和组织损伤。细胞因不同模式的程序性细胞死亡而死,包括凋亡和 坏死性。细胞凋亡的细胞死亡是健康组织生理学的正常成分,它是由细胞平衡的 分裂并保持正常的组织大小和功能。细胞凋亡的细胞死亡是耐受性的,非 - 炎症,并与坏死作用形成鲜明对比,这是病理和炎症性的。坏死性涉及 相互作用的丝氨酸/苏氨酸蛋白激酶RIPK1,RIPK3和RIPK3的形成 坏死作用效应子混合谱系激酶结构域样蛋白(MLKL)。直到最近,还认为坏死性 在控制感染的控制中起主要作用,主要是反对病毒阻滞的故障安全策略 凋亡。然而,在小鼠模型中的研究表明,细胞凋亡的成分缺乏 诸如caspase-8或FADD之类的机械导致胚胎致死性驱动,并依赖于 RIPK3和MLKL。其他研究使用肠上皮中caspase-8或FADD的条件缺失的研究 发现阻止介导稳态凋亡会导致肠道炎症的途径 与RIPK3水平升高和坏死性相关。确实,编程细胞死亡显着增加 肠上皮细胞(IEC)已有报道 损害与感染的增强和肿瘤坏死因子(TNF)-a的水平增加有关 细胞死亡的重要介质。使用新型的小鼠模型,我们可以诱导触发IEC的坏死性, 我们将确定IEC坏死性如何影响肠内稳态,我们将定义的性质 炎症反应。我们以前的工作已经确定了肠内的稳态凋亡 上皮是免疫抑制和耐受性的主要驱动力,印记肠单核吞噬细胞 (MNP)带有“注射抑制”和“诱导调节性CD4 T细胞”的转录特征。这里 我们将定义坏死性如何影响MNP反应。我们将研究 对坏死性IEC响应并在各种先天的功能中响应其功能的小肠道MNP种群 与产生炎症介质有关的免疫功能,先天性淋巴样细胞的调节 功能以及CD4 T辅助细胞分化。我们获得的知识将定义坏死性 驱动先天和适应性细胞的炎症反应,作为路线图 其他组织中坏死性的后果,并为开发新疗法奠定了基础 对于慢性炎症性疾病,例如IBD。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Spotlight on TAP and its vital role in antigen presentation and cross-presentation.
  • DOI:
    10.1016/j.molimm.2021.12.013
  • 发表时间:
    2022-03
  • 期刊:
  • 影响因子:
    3.6
  • 作者:
    Mantel, Ian;Sadiq, Barzan A. A.;Blander, J. Magarian
  • 通讯作者:
    Blander, J. Magarian
A Comprehensive Experimental Guide to Studying Cross-Presentation in Dendritic Cells In Vitro.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julie Magarian Blander其他文献

Julie Magarian Blander的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julie Magarian Blander', 18)}}的其他基金

Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation
通过非规范交叉呈递动员不依赖 TAP 的 CD8 T 细胞
  • 批准号:
    10659785
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Modulating XIAP for the Treatment of Inflammatory Bowel Disease
调节 XIAP 治疗炎症性肠病
  • 批准号:
    10727185
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Toll-like receptor control of endocytic antigen cross-presentation
Toll 样受体控制内吞抗原交叉呈递
  • 批准号:
    10735354
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10557150
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10453097
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
  • 批准号:
    10043494
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:
Role of apoptosis in the intestinal epithelium during homeostasis and disease
肠上皮细胞凋亡在稳态和疾病过程中的作用
  • 批准号:
    9926879
  • 财政年份:
    2017
  • 资助金额:
    $ 21.19万
  • 项目类别:
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade
TAP 阻断后树突状细胞中的非典型交叉呈递
  • 批准号:
    9404238
  • 财政年份:
    2017
  • 资助金额:
    $ 21.19万
  • 项目类别:
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
新型维生素疫苗配方结合了死疫苗的安全性和活疫苗的功效
  • 批准号:
    9357501
  • 财政年份:
    2016
  • 资助金额:
    $ 21.19万
  • 项目类别:
Control of protective immunity by innate pathways sensing bacterial viability
通过感知细菌活力的先天途径控制保护性免疫
  • 批准号:
    8295078
  • 财政年份:
    2012
  • 资助金额:
    $ 21.19万
  • 项目类别:

相似海外基金

Midlife cardiovascular stress physiology and preclinical cerebrovascular disease
中年心血管应激生理学与临床前脑血管疾病
  • 批准号:
    10720054
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
PET Tracer for Imaging of Lung Inflammation
用于肺部炎症成像的 PET 示踪剂
  • 批准号:
    10682270
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Development of antibodies to specific cell surface markers to assess macrophage polarization during Adenovirus 14 and 14p1 infection in the Syrian hamster
开发针对特定细胞表面标记物的抗体,以评估叙利亚仓鼠腺病毒 14 和 14p1 感染期间的巨噬细胞极化
  • 批准号:
    10725702
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
ShEEP Request for MESO SECTOR S 600MM Ultra-Sensitive Plate Imager
ShEEP 请求 MESO SECTOR S 600MM 超灵敏板成像仪
  • 批准号:
    10741205
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了